← BIOCRYST PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $26.4m |
$25.2m
-4.43%
|
$20.7m
-18.00%
|
$48.8m
+136.45%
|
$17.8m
-63.53%
|
$157.2m
+782.38%
|
$270.8m
+72.31%
|
$331.4m
+22.37%
|
$450.7m
+36.00%
|
$874.8m
+94.10%
|
$940.6m
+7.52%
|
|
| Cost of Revenue | $2.3m |
$1.1m
-50.28%
|
$85.4m
+7374.52%
|
$3.7m
-95.63%
|
$1.6m
-58.40%
|
$7.2m
+366.39%
|
$6.4m
-11.36%
|
$4.5m
-30.07%
|
$12.3m
+173.80%
|
$19.1m
+55.47%
|
$20.9m
+9.70%
|
|
| Gross Profit (Calculated) (derived) | $24.1m |
$24.0m
-0.05%
|
($64.7m)
-369.11%
|
$45.1m
+169.71%
|
$16.3m
-63.95%
|
$149.9m
+822.03%
|
$264.4m
+76.35%
|
$326.9m
+23.64%
|
$438.4m
+34.11%
|
$855.8m
+95.18%
|
— | |
| Research and Development Expense | $61.0m | $67.0m | $84.9m | $107.1m | $123.0m | $208.8m | $253.3m | $216.6m | $174.6m | $166.1m | $895.5m | |
| Selling, General and Administrative Expense | $11.3m | $13.9m | $29.5m | $37.1m | $67.9m | $118.8m | $159.4m | $213.9m | $266.1m | $348.6m | $337.3m | |
| Operating Lease, Expense | — | — | — | $1.5m | $1.8m | $1.8m | $2.5m | $2.0m | $2.3m | $2.0m | — | |
| Restructuring Costs | — | — | — | — | — | — | — | — | — | $6.3m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($48.6m) |
($57.4m)
-18.11%
|
($94.2m)
-64.11%
|
($99.5m)
-5.56%
|
($174.8m)
-75.71%
|
($177.7m)
-1.70%
|
($148.4m)
+16.48%
|
($103.7m)
+30.13%
|
($2.5m)
+97.55%
|
$341.0m
+13508.93%
|
($313.2m)
-191.84%
|
|
| Interest Expense, Debt | $6.5m | $8.6m | $9.2m | $11.9m | $14.5m | $59.3m | $99.1m | $108.2m | $98.5m | $78.9m | $75.3m | |
| Interest Expense (non-operating) | $6.5m | $8.6m | $9.2m | $11.9m | $14.5m | $59.3m | $99.1m | $108.2m | $98.5m | $78.9m | $75.3m | |
| Interest and Other Income | $793k | $1.0m | $2.3m | $1.9m | — | — | — | — | $14.7m | $10.7m | — | |
| Other Income | — | — | — | — | — | — | — | $0 | $0 | $12.1m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $48.6m | $57.4m | $94.2m | $99.5m | ($176.6m) | ($159.6m) | ($225.1m) | ($206.7m) | ($62.5m) | $172.6m | ($381.2m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $48.6m | $57.4m | $94.2m | $99.5m | $174.8m | ($181.8m) | ($244.4m) | ($226.2m) | ($87.0m) | $267.4m | ($381.2m) | |
| Current Income Tax Expense (Benefit) | — | — | — | $0 | $0 | $2.3m | $2.7m | $992k | $2.3m | $4.7m | $3.5m | |
| Income Tax Expense (Benefit) | — | $0 | $0 | $0 | $0 | $2.3m | $2.7m | $310k | $1.9m | $3.5m | $3.5m | |
| Net Income (Loss) Attributable to Parent | ($55.1m) |
($65.8m)
-19.29%
|
($101.3m)
-53.92%
|
($108.9m)
-7.55%
|
($182.8m)
-67.88%
|
($184.1m)
-0.68%
|
($247.1m)
-34.26%
|
($226.5m)
+8.33%
|
($88.9m)
+60.77%
|
$263.9m
+396.87%
|
($384.7m)
-245.79%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($1.09) | ($1.03) | ($1.33) | ($1.18) | ($0.43) | $1.26 | ($1.35) | |
| Earnings Per Share, Diluted | ($0.75) | ($0.78) | ($0.98) | ($0.94) | ($1.09) | ($1.03) | ($1.33) | ($1.18) | ($0.43) | $1.21 | ($1.40) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 167.3m | 179.1m | 185.9m | 192.2m | 206.7m | 209.9m | 229.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 73.7m | 84.5m | 103.2m | 115.6m | 167.3m | 179.1m | 185.9m | 192.2m | 206.7m | 218.6m | 234.0m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $75.0m | $82.6m | $114.9m | $148.3m | $192.6m | $334.9m | $419.3m | $435.1m | $453.3m | $533.8m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | — | — | — | — | $85.1m | — |